1262. Dolutegravir Plus 3TC In Antiretroviral Experienced Adults: Immunovirological Outcomes In a Multicenter Retrospective Cohort In Spain

BACKGROUND: Dolutegravir-based dual therapies for treating people living with HIV (PLHIV) are strategies strongly recommended in several practice guidelines. The safety and efficacy combination of Dolutegravir (DTG) plus 3TC as a switching strategy in virologically suppressed patients was demonstrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Buzón-Martín, Luis, Dueñas Gutierrez, Carlos, Iribarren, José Antonio, de los Santos, Ignacio, Santiago, Alberto Diaz-De, Morán-Rodríguez, Miguel Ángel, Pousada, Guillermo, Rico, Claudia González, García, Estela Moreno, Ferreira, Eva, Gómez, Alicia Iglesias, gómez, Cristina Martín, Barquero, Julia gómez, Egido Murciano, Miguel V, Troya, Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752996/
http://dx.doi.org/10.1093/ofid/ofac492.1093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752996/
http://dx.doi.org/10.1093/ofid/ofac492.1093

Ejemplares similares